New Zealand markets open in 5 hours 58 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
90.94-0.58 (-0.63%)
At close: 04:00PM EDT
90.88 -0.06 (-0.07%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close91.52
Bid90.92 x 800
Ask92.00 x 800
Day's range90.63 - 92.57
52-week range50.44 - 100.88
Avg. volume3,650,538
Market cap407.891B
Beta (5Y monthly)0.24
PE ratio (TTM)43.30
EPS (TTM)2.10
Earnings dateN/A
Forward dividend & yield1.03 (1.13%)
Ex-dividend date18 Aug 2023
1y target est77.90
  • Zacks

    3 Stocks to Focus on as Demand for Obesity Drugs Booms

    With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market

  • Motley Fool

    Is Novo Nordisk a Good Passive Income Stock?

    Passive income investors know that when there's a business that's proven to throw off a lot of cash consistently over time, it might be a good idea to hold its shares to capture safe and reliable dividends for the long haul. Novo Nordisk (NYSE: NVO) is an obvious candidate to consider right now. Thanks to its blockbuster drug Ozempic and a pipeline that's chock-full of other potential winners, Novo Nordisk seems to have most of the makings of a great dividend stock.

  • Financial Times

    Obesity drugmaker’s expansion raises dominance worries for Denmark

    Ozempic, a diabetes treatment that celebrities take to lose weight, and Wegovy, an anti-obesity medication, have propelled Novo Nordisk to become Europe’s most valuable company and single-handedly stopped Denmark from falling into recession. At $410bn, Novo Nordisk’s market capitalisation is now larger than Denmark’s annual GDP of $400bn last year, raising concerns among officials and business figures that the country’s fortunes have become too closely tied to a single company. “The way that we look at it is that in Denmark we have a two-speed economy: the pharmaceutical industry — and the rest,” said Thomas Harr, chief economist at Denmark’s central bank.